Over the last few decades, medicine has made tremendous strides in the treatment of infectious disease, cardiovascular illness, and other life-threatening conditions. However, most metastatic cancer is treated today with similar methods that were used twenty years ago, namely a combination of surgery, chemotherapy, and radiation. Aside from sporadic use of monoclonal antibodies and individualized cancer vaccines, cancer therapy has not advanced significantly in recent years.
Immunovative Therapies Ltd., a small, relatively new biotech company in Israel, is using a novel approach to treat metastatic tumors. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, is developing unique drugs that “wake-up” a patient's immune system and enable it to attack and kill metastatic cells. Dr. Michael Har-Noy's work may usher in a whole new era of cancer therapy.
Dr. Michael Har-Noy, a world-renowned and recognized immunologist and scientist, spent many years at Hadassah Medical Center in Israel studying bone marrow transplant patients and defining the immunologic characteristics of successful transplant patients that did not develop graft versus host disease. At Immunovative Therapies, Dr. Michael Har-Noy has used this information to formulate complex cellular-based compounds that, when administered to a cancer patient, provoke the patient's own immune system to attack the administered drug and in the process, attack the tumor as well.
At Immunovative Therapies, Ltd., Dr. Michael Har-Noy has developed and is testing three prototype compounds; AlloStimTM, CryoStimTM, and AlloVaxTM. As opposed to the anti- tumor effect of a bone marrow transplant, these drugs provoke a tumor-killing immune response that has no potential for toxicity, as it is the patient's own immune system, and not a foreign transplant, that initiates the tumor-killing process.
Medical scientists have as yet been unable to consistently stimulate a patient's immune system to seek out and kill cancerous cells. Dr. Michael Har-Noy of Immunovative Therapies, Ltd. appears to have discovered a way to facilitate this process, and in doing so may soon completely change the way cancer is treated.